Nitric oxide-releasing glycosaminoglycans for treating complex wounds
释放一氧化氮的糖胺聚糖用于治疗复杂伤口
基本信息
- 批准号:10584269
- 负责人:
- 金额:$ 38.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAdhesionsAffectAmputationAnti-Bacterial AgentsAntibiotic ResistanceAntibioticsBacterial Antibiotic ResistanceBiological AssayBiopolymersCell Culture TechniquesCell ProliferationCellsComplexDermalDevelopmentDiabetes MellitusDiabetic mouseDiseaseDoseEpitheliumFailureFrequenciesFutureGasesGlycosaminoglycansGoalsHandHigh PrevalenceHumanImmuneImmune responseImpaired healingImpairmentIn VitroIndividualInfectionInflammationInflammatoryKnowledgeMacrophageMolecular WeightMonitorMorbidity - disease rateMusNitric OxideNitric Oxide DonorsNon-Insulin-Dependent Diabetes MellitusPatientsPatternPhenotypePhysiologyPlayPopulationProcessProductionPropertyPunch BiopsyResearchResistanceRoleSeriesSignal TransductionSignaling MoleculeSkin TissueStructureSulfateSystemSystems BiologyTherapeuticTherapeutic InterventionTimeTissue ModelTissuesToxic effectTreatment EfficacyWound InfectionWound healing therapycell motilitychronic woundclinical translationdiabetic ulcerefficacy evaluationimmune functionimmunoregulationin vivomicrobialmigrationmonocytemortalitymouse modelneutrophilpathogenprogramsresistant strainresponse to injuryscaffoldsuccesstherapeutically effectivetissue reconstructiontissue repairtranslational therapeuticstreatment responsetwo-dimensionalwoundwound closurewound healingwound treatment
项目摘要
SUMMARY
The delayed healing observed in chronic wounds is exacerbated by persistent microbial infections and non-
resolving inflammation. Furthermore, the emergence of antibiotic-resistant bacteria has limited the use of these
agents for treating infected wounds. Adding to the complexity of chronic wound treatment, infection is usually
not the sole cause of wound chronicity. Underlying diseases such as diabetes leave individuals prone to infection
by affecting the host immune responses, including inflammatory cell migration, cell signaling, and effector
function. An ideal wound healing therapeutic must thus address the impairment of the host immune response while also
possessing antibacterial activity. Due to the high prevalence of chronic wound-related amputations and mortality, the need
for such a multi-action therapeutic is urgent. Nitric oxide (NO) is an endogenous signaling molecule that represents
an attractive, alternative therapeutic for treating chronic wounds due to its innate antibacterial and
immunomodulatory function in human physiology. We have pioneered the development of macromolecular
NO donor systems that store and spontaneously release NO in dissolved form (i.e., not as a gas) at
therapeutically relevant levels. We now aim to develop NO-releasing glycosaminoglycan biopolymers (GAGs)
as wound healing therapeutics. GAGs are naturally occurring biopolymers that are immunomodulatory and
known to be involved in wound healing physiology. We hypothesize that combining the multi-faceted roles of
GAGs and NO will allow for a therapeutic that effectively: 1) eradicates wound pathogens; 2) modulates
inflammation; and, 3) promotes re-epithelialization to facilitate timely wound closure.
The objective of this project is to define the roles of GAG molecular weight, sulfation patterns and NO-release
properties as they related to antibacterial and pro-wound healing activities. In developing a new class of wound-
healing therapeutics, we will characterize cell proliferation, adhesion, and migration as a function of NO
payloads and GAG structure using cell culture assays and a three-dimensional human skin tissue model. We
will evaluate the effect of NO-releasing GAGs on innate immune cell plasticity using primary human cell
systems. We will then determine the therapeutic efficacy of the most promising NO-releasing GAG derivatives
on antibacterial action, inflammation, and wound closure as a function of infection and diabetes. An iterative
approach will be taken to determine the optimal dose, time, and frequency of therapeutic intervention. A
systems biology approach will be used to elucidate mechanisms of efficacy and failure, which will inform clinical
translation of these therapeutic approaches. This new research program will allow us to build upon our previous
successes in developing NO-releasing macromolecular scaffolds, but now with a focus on wound healing. Our
goal is to develop a therapeutic that treats infection and promotes wound healing in populations afflicted by chronic wounds.
总结
在慢性伤口中观察到的延迟愈合因持续的微生物感染和非细菌感染而加剧。
消除炎症。此外,耐药性细菌的出现限制了这些抗生素的使用。
用于治疗感染伤口的药剂。增加了慢性伤口治疗的复杂性,感染通常是
不是伤口慢性化的唯一原因糖尿病等潜在疾病使个人易于感染
通过影响宿主免疫应答,包括炎性细胞迁移、细胞信号传导和效应物,
功能因此,理想的伤口愈合治疗剂必须解决宿主免疫应答的损伤,同时还
具有抗菌活性。由于慢性伤口相关截肢和死亡率高,
对于这样一种多作用治疗是迫切的。一氧化氮(NO)是一种内源性信号分子,
由于其固有的抗菌性,
免疫调节功能。我们率先开发了高分子
储存和自发释放溶解形式的NO的NO供体系统(即,不作为气体),
治疗相关水平。我们现在的目标是开发释放NO的糖胺聚糖生物聚合物(GAG)
作为伤口愈合治疗剂。GAG是天然存在的生物聚合物,其具有免疫调节作用,
已知与伤口愈合生理学有关。我们假设,结合多方面的作用,
GAG和NO将允许有效的治疗:1)根除伤口病原体; 2)调节
炎症;和3)促进上皮再生以促进及时的伤口闭合。
本项目的目的是确定GAG分子量,硫酸化模式和NO释放的作用
因为它们与抗菌和促伤口愈合活性有关。在发展一种新的伤口-
愈合疗法,我们将表征细胞增殖,粘附和迁移作为一个功能的NO
使用细胞培养测定和三维人体皮肤组织模型,对有效载荷和GAG结构进行了分析。我们
将使用原代人细胞评估NO释放GAG对先天免疫细胞可塑性的影响
系统.然后,我们将确定最有前途的NO释放GAG衍生物的治疗效果
对抗菌作用、炎症和作为感染和糖尿病的函数的伤口闭合的影响。迭代
将采取一种方法来确定治疗干预的最佳剂量、时间和频率。一
系统生物学方法将用于阐明有效性和失败的机制,这将为临床提供信息。
这些治疗方法的翻译。这项新的研究计划将使我们能够建立在我们以前的
在开发NO释放大分子支架方面取得了成功,但现在专注于伤口愈合。我们
目标是开发一种治疗感染并促进慢性伤口患者伤口愈合的治疗剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark H Schoenfisch其他文献
Mark H Schoenfisch的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark H Schoenfisch', 18)}}的其他基金
Nitric oxide-releasing hyaluronic acid therapeutics for treating periodontal disease
释放一氧化氮的透明质酸疗法用于治疗牙周病
- 批准号:
10657158 - 财政年份:2023
- 资助金额:
$ 38.14万 - 项目类别:
Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors
糖尿病和一氧化氮释放持续时间对体内葡萄糖生物传感器分析性能的作用
- 批准号:
10263316 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Nitric oxide-releasing dendrimers for the treatment of periodontal disease
释放一氧化氮的树枝状聚合物用于治疗牙周病
- 批准号:
8927301 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Nitric oxide-releasing dendrimers for the treatment of periodontal disease
用于治疗牙周病的释放一氧化氮的树枝状聚合物
- 批准号:
9261511 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors
糖尿病和一氧化氮释放持续时间对体内葡萄糖生物传感器分析性能的作用
- 批准号:
10418787 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors
糖尿病和一氧化氮释放持续时间对体内葡萄糖生物传感器分析性能的作用
- 批准号:
10673705 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors
糖尿病和一氧化氮释放持续时间对体内葡萄糖生物传感器分析性能的作用
- 批准号:
9185309 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Nitric oxide-releasing dendrimers for the treatment of periodontal disease
释放一氧化氮的树枝状聚合物用于治疗牙周病
- 批准号:
9104134 - 财政年份:2015
- 资助金额:
$ 38.14万 - 项目类别:
Nitric oxide-releasing cystic fibrosis therapeutics
释放一氧化氮的囊性纤维化疗法
- 批准号:
8968231 - 财政年份:2014
- 资助金额:
$ 38.14万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 38.14万 - 项目类别:
Research Grant